Compass Therapeutics
CMPX
103 hedge funds and large institutions have $281M invested in Compass Therapeutics in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 41 reducing their positions, and 24 closing their positions.
37% more capital invested
Capital invested by funds: $206M → $281M (+$75.4M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.16% less ownership
Funds ownership: 78.44% → 78.28% (-0.16%)
5% less funds holding
Funds holding: 108 → 103 (-5)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
41% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 41
99% less call options, than puts
Call options by funds: $85K | Put options by funds: $6.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$14.7M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.13M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.04M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$1.5M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.7M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.82M |
| 3 |
BlackRock
New York
|
-$1.44M |
| 4 |
Morgan Stanley
New York
|
-$1.22M |
| 5 |
SG Americas Securities
New York
|
-$1.17M |
CMPX Hedge Fund Activity: Q2 2025 in Review
103 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2025, worth a combined $281M — up 37% from $206M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CMPX and 19 opened new positions — a net loss of 5 holders — while 41 trimmed existing stakes and 24 added.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $14.7M. The largest seller was OrbiMed, cutting an estimated $14.7M.
- 103 institutional investors held Compass Therapeutics (CMPX) as of Q2 2025, down from 108 in Q1 2025.
- Funds reported $281M of Compass Therapeutics stock for Q2 2025, up 37% quarter-over-quarter.
- 19 funds opened new Compass Therapeutics positions in Q2 2025 and 24 closed out, a net change of -5 holders.
- The largest Compass Therapeutics buyer in Q2 2025 was Suvretta Capital Management, an estimated $14.7M added.
- The largest Compass Therapeutics seller in Q2 2025 was OrbiMed, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2025.